Last updated: September 24, 2026
Abraxis Bioscience, LLC v. Actavis LLC, No. 2:16-cv-01925, was a Hatch-Waxman patent action in the U.S. District Court for the District of New Jersey concerning Actavis’s abbreviated new drug application for a generic version of Abraxane, an albumin-bound paclitaxel product. Abraxis alleged that Actavis’s ANDA filing infringed Abraxane-related patents under 35 U.S.C. § 271(e)(2).
The case was an ANDA certification dispute, not a conventional commercial-infringement action. Its commercial significance arose from the potential to delay generic entry into a market in which Abraxane was protected by formulation, composition, and method-of-use patents. The public docket does not establish a final merits judgment invalidating or upholding the asserted patent claims.
What drug and product were at issue in Abraxis Bioscience v. Actavis?
The product was Abraxane for Injectable Suspension, the branded formulation of paclitaxel bound to human albumin nanoparticles.
| Product |
Active ingredient |
Dosage form |
NDA holder at relevant period |
FDA approval |
| Abraxane |
Paclitaxel, albumin-bound particles |
Intravenous injectable suspension |
Abraxis BioScience, later Celgene |
NDA 021660, 2005 |
Abraxane differs from conventional paclitaxel products because paclitaxel is formulated as albumin-bound nanoparticles rather than being solubilized with Cremophor EL. The formulation was developed to provide intravenous delivery without the conventional solvent system used in older paclitaxel products.
FDA-approved indications included:
- Metastatic breast cancer after failure of combination chemotherapy or relapse within six months of adjuvant chemotherapy.
- Locally advanced or metastatic non-small-cell lung cancer in combination with carboplatin.
- Metastatic adenocarcinoma of the pancreas in combination with gemcitabine.
The pancreatic cancer indication was commercially important because it generated a method-of-use patent layer separate from the underlying product and formulation protection.[1]
What patents were involved in the Actavis Abraxane case?
The case concerned Orange Book-listed Abraxane patent rights asserted in response to Actavis’s ANDA. The principal patent associated with the litigation was U.S. Patent No. 8,853,260, directed to methods of treating cancer using albumin-bound paclitaxel. The patent family formed part of Abraxis’s broader Abraxane estate.
| Patent |
General subject matter |
Relevance to Abraxane |
| U.S. Patent No. 8,853,260 |
Methods of treating cancer using albumin-bound paclitaxel |
Method-of-use protection, including regimen-based treatment claims |
| U.S. Patent No. 8,617,596 |
Albumin-bound paclitaxel treatment technology |
Related patent-family protection |
| U.S. Patent No. 8,445,011 |
Albumin-bound paclitaxel and therapeutic-use technology |
Related formulation or use protection |
| U.S. Patent No. 7,820,788 |
Albumin-bound paclitaxel composition and delivery technology |
Earlier Abraxane platform protection |
The relevant patent claims were not identical in scope. Some focused on the albumin-bound paclitaxel composition or delivery system. Others focused on administering the product according to a specified dosing schedule, cancer indication, or combination regimen.
The litigation therefore presented two distinct patent risks:
- Whether Actavis’s proposed product would infringe the listed product or formulation claims.
- Whether the proposed labeling would induce infringement of method-of-use claims.
Was Actavis’s ANDA a Paragraph IV challenge?
Yes. The action was filed under the Hatch-Waxman framework after Actavis notified Abraxis of an ANDA containing a Paragraph IV certification.
A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Once the brand owner receives notice and files an infringement action within the statutory period, the FDA generally imposes a 30-month stay on final ANDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions and court action.
The filing of the case created the standard regulatory consequences:
- Abraxis obtained the opportunity to litigate before generic approval.
- Actavis faced a potential 30-month approval stay.
- The case required construction of the asserted claims and evaluation of infringement and validity.
- A final launch date depended on the litigation outcome, settlement terms, patent expiration, and any applicable regulatory exclusivity.
What was the litigation timeline?
The publicly identified procedural milestones are summarized below.
| Date or period |
Event |
| March 31, 2016 |
Abraxis filed the patent infringement action against Actavis in the District of New Jersey. |
| 2016 |
Actavis’s ANDA and Paragraph IV certification formed the basis for the § 271(e)(2) infringement claims. |
| 2016-2017 |
The parties litigated the asserted Abraxane patent rights and related Hatch-Waxman issues. |
| Later proceedings |
The docket was resolved without a publicly reported merits decision establishing broad invalidity of the Abraxane patent estate. |
The case number identifies the action as No. 2:16-cv-01925. The public record should be distinguished from later Abraxane-related proceedings involving other generic applicants, patent families, or corporate successors.
Did the court invalidate the Abraxane patents?
No reported final merits ruling in this action established that the Abraxane patent estate was invalid in its entirety.
That distinction matters. A Hatch-Waxman case can end through:
- A confidential settlement.
- Dismissal after a negotiated launch date.
- Amendment or withdrawal of an ANDA.
- A judgment on a limited patent claim.
- A ruling that does not affect other patents or other generic applicants.
The absence of a reported invalidity judgment in this case means the litigation did not create a broad, generally applicable invalidity precedent against the Abraxane portfolio. Other defendants remained able to challenge the same or related patents in separate proceedings.
What patent claims created the main generic-entry risk?
Formulation and composition claims
Formulation claims protect the technical configuration of the product. For Abraxane, relevant subject matter included paclitaxel associated with albumin particles and pharmaceutical compositions suitable for intravenous administration.
These claims can create a direct-infringement risk because the generic product itself may embody the claimed composition. A generic applicant cannot ordinarily avoid such claims through a label carve-out if the proposed product necessarily contains the claimed structure.
Method-of-use claims
Method-of-use claims protect how the drug is administered or for which indication it is used. Abraxane-related claims addressed treatment of cancer with albumin-bound paclitaxel, including dosing and combination-treatment regimens.
Method claims can be narrower than composition claims. A generic applicant may seek a section viii statement or a skinny label excluding a patented indication. That approach can reduce, but not always eliminate, induced-infringement risk. If the remaining label, promotional materials, or prescribing environment encourages the patented use, the brand owner may still assert induced infringement under 35 U.S.C. § 271(b).
Manufacturing and process claims
Manufacturing claims may cover the preparation of albumin-bound paclitaxel particles, particle-size control, drug loading, or processing conditions. These claims can be difficult to evaluate publicly because ANDA manufacturing information is confidential.
Process patents generally present a different enforcement profile from product patents. They may increase litigation cost and discovery burden, but they do not always prevent an applicant from launching a product manufactured through a noninfringing process.
What was the FDA and Orange Book status?
Abraxane was approved under NDA 021660. The FDA Orange Book listed Abraxane-related patents during the period relevant to generic development and litigation.[2]
The principal regulatory protections were:
| Protection |
Effect |
| NDA approval |
Permitted commercial marketing of Abraxane for approved indications |
| Orange Book listing |
Required ANDA applicants to address listed patents |
| Paragraph IV notice |
Triggered patent litigation risk and potential 30-month stay |
| Method-of-use listing |
Allowed protection of particular indications or regimens |
| New clinical indication exclusivity |
Could delay approval for the protected indication even if patent issues were resolved |
FDA approval of a generic Abraxane product would not itself resolve every patent issue. Approval, patent expiry, settlement restrictions, and the scope of any carved-out label are separate questions.
When did Abraxane lose exclusivity?
Abraxane did not have a single exclusivity end date. Its market protection consisted of several overlapping rights.
The earliest Abraxane platform patents reached the end of their effective terms before the later method-of-use patents. Later patents, including method-of-treatment patents associated with the pancreatic cancer regimen, extended potential barriers beyond the original composition protection.
The practical generic-entry date therefore depended on:
- The specific patent claims asserted against the applicant.
- The patent-term-adjusted expiration dates listed by the FDA.
- Whether the applicant prevailed on invalidity or noninfringement.
- Whether the applicant carved out a patented indication.
- Any settlement or license restricting launch.
- FDA approval and regulatory exclusivity.
A patent expiration date alone did not guarantee immediate entry. Conversely, an Orange Book listing did not guarantee that every claim would survive a validity challenge.
Was biosimilar litigation relevant to this case?
No. Abraxane is a small-molecule drug product for Hatch-Waxman purposes, not a biologic subject to the biosimilar pathway under the Public Health Service Act.
The relevant competitive threat was a generic ANDA, not a biosimilar application. The distinction affects:
- The approval pathway.
- The patent-certification framework.
- The statutory information exchange.
- The regulatory exclusivity rules.
- The terminology used for the competing product.
Although Abraxane uses albumin nanoparticles as a delivery platform, that formulation characteristic does not convert the product into a biologic for FDA approval purposes.
Did Abraxis and Actavis enter a settlement agreement?
The case did not produce a widely reported public settlement agreement containing a detailed, enforceable launch date or royalty structure. The public record does not support treating the action as a merits decision that cleared the Abraxane patents for all generic applicants.
If the case ended through settlement or negotiated dismissal, its principal commercial effect would have been applicant-specific. A settlement with Actavis would not automatically bind Teva, Sandoz, Apotex, Fresenius Kabi, or another ANDA applicant.
The absence of public settlement terms also limits conclusions about:
- The agreed generic launch date.
- Whether Actavis received a license.
- Whether the agreement included a payment.
- Whether the settlement imposed supply, formulation, or manufacturing restrictions.
Which companies challenged Abraxane patent protection?
Abraxane faced generic competition from multiple pharmaceutical companies and ANDA applicants over time. The relevant competitive set included Actavis and other generic manufacturers seeking approval for paclitaxel protein-bound particles.
The corporate identity of an ANDA applicant can change during litigation through acquisition, divestiture, or transfer of the ANDA. Actavis’s generic business was associated with Allergan and later AbbVie corporate structures, while Abraxis became part of Celgene and Celgene was later acquired by Bristol Myers Squibb.
Corporate succession matters because the patent owner, NDA holder, ANDA applicant, and litigation defendant may not be the same entities at different points in the product’s commercial history.
How strong was the Abraxane patent estate?
The estate was strongest against a generic that:
- Used the same albumin-bound paclitaxel formulation.
- Sought approval for all major Abraxane indications.
- Included the patented pancreatic cancer regimen.
- Manufactured the product through a process covered by an asserted claim.
- Could not rely on a commercially meaningful label carve-out.
The estate was weaker where a generic could:
- Omit a patented indication.
- Avoid a claimed dosing schedule.
- Use a noninfringing manufacturing process.
- Challenge later-issued method patents independently.
- Rely on expiration of older composition patents.
The strategic value of the estate came from layering. Even if an early platform patent expired, later formulation and method patents could continue to increase the cost and timing risk of generic entry.
What generic launch scenarios followed from the case?
Three launch scenarios were commercially plausible.
| Scenario |
Effect on Abraxane |
| Actavis defeats the asserted patents |
Earlier generic entry and rapid price erosion |
| Actavis settles for a future launch date |
Delayed but defined generic entry |
| Actavis receives approval with a carved-out label |
Partial competition, initially excluding one or more protected indications |
The third scenario is particularly important for Abraxane because the pancreatic cancer indication had substantial clinical and commercial relevance. A carve-out could permit competition in breast cancer or lung cancer while preserving some protection for the patented pancreatic regimen.
What was the revenue exposure?
Abraxane was a material revenue product for Abraxis, Celgene, and later Bristol Myers Squibb. Revenue exposure depended on the timing and number of generic entrants.
A first generic competitor could produce substantial price erosion, particularly if it obtained approval for the principal indications and had adequate manufacturing capacity. The effect would be greater if several ANDA applicants entered near the same date.
The financial analysis should separate:
- Revenue protected by composition patents.
- Revenue protected by method-of-use patents.
- Revenue associated with the pancreatic cancer indication.
- U.S. revenue versus international sales.
- Gross sales versus net sales after rebates and discounts.
- The timing of generic approval and actual commercial launch.
The docket alone does not establish a reliable case-specific revenue figure or a confirmed Actavis launch date.
Key Takeaways
- Abraxis sued Actavis in the District of New Jersey in 2016 over an ANDA for generic Abraxane.
- The case was a Paragraph IV Hatch-Waxman action under 35 U.S.C. § 271(e)(2).
- The dispute involved Abraxane’s albumin-bound paclitaxel technology, including formulation and method-of-use protection.
- U.S. Patent No. 8,853,260 was a principal patent associated with the litigation.
- The case did not produce a publicly reported broad invalidity judgment against the Abraxane patent estate.
- Abraxane is regulated as a small-molecule drug, so biosimilar law was not relevant.
- Generic-entry timing depended on patent scope, patent-term dates, FDA approval, label carve-outs, and any confidential settlement terms.
- Corporate ownership later moved from Abraxis to Celgene and then to Bristol Myers Squibb, while Actavis became part of broader Allergan and AbbVie structures.
FAQs About Abraxis Bioscience v. Actavis
What was the docket number for the Abraxane Actavis lawsuit?
The docket number was 2:16-cv-01925 in the U.S. District Court for the District of New Jersey.
What product did Actavis seek to copy?
Actavis sought approval for a generic version of Abraxane, an intravenous albumin-bound paclitaxel product marketed under NDA 021660.
Was the lawsuit based on a Paragraph IV certification?
Yes. Abraxis filed the action after receiving Actavis’s Paragraph IV notice concerning Abraxane-related patents.
Did the lawsuit concern a biosimilar?
No. The case concerned an ANDA for a generic drug product. Abraxane was not litigated through the biosimilar pathway.
Did the case establish that Abraxane patents were invalid?
No publicly reported final merits ruling in this action established broad invalidity of the Abraxane patent estate.
References
- U.S. Food and Drug Administration. (2023). Abraxane label: Paclitaxel protein-bound particles for injectable suspension.
- U.S. Food and Drug Administration. (2016). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. District Court for the District of New Jersey. (2016). Abraxis Bioscience, LLC v. Actavis LLC, No. 2:16-cv-01925.
- U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,853,260: Methods of treating cancer using albumin-bound paclitaxel.
- U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,617,596.
- U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,445,011.
